Sagimet Biosciences Inc - Class A

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in conditions caused by overproduction of the fatty acid palmitate. The company's lead candidate, denifanstat, is an oral once-daily FASN inhibitor being developed for moderate to severe acne in the U.S. market, with plans for a registrational Phase 3 trial. Denifanstat has already demonstrated clinical success in a Phase 3 trial in China conducted by Ascletis, Sagimet's license partner for Greater China, and an NDA was accepted by China's NMPA. The company also has a follow-on FASN inhibitor, TVB-3567, in a Phase 1 first-in-human trial for acne, and is developing a topical FASN inhibitor formulation. Beyond dermatology, denifanstat showed positive Phase 2b results in MASH and holds FDA Breakthrough Therapy designation for that indication, though further MASH development is contingent on securing non-dilutive funding. The company has no approved products and generates no revenue. Sagimet trades on Nasdaq under the ticker SGMT and was recently added to the Russell 2000 and Russell 3000 indices. Updated Aug 11, 2026